Cargando…

A Double‐blind, Placebo‐controlled, Multicenter, Prospective, Randomized Study of Beraprost Sodium Treatment for Cats with Chronic Kidney Disease

BACKGROUND: Chronic kidney disease (CKD) is a common progressive and irreversible disease in cats. The efficacy and safety of beraprost sodium (BPS) in cats with CKD have not been evaluated. HYPOTHESIS/OBJECTIVES: To evaluate the efficacy and safety of BPS in the treatment of cats with CKD, as compa...

Descripción completa

Detalles Bibliográficos
Autores principales: Takenaka, M., Iio, A., Sato, R., Sakamoto, T., Kurumatani, H.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5787173/
https://www.ncbi.nlm.nih.gov/pubmed/29131397
http://dx.doi.org/10.1111/jvim.14839
_version_ 1783295878273957888
author Takenaka, M.
Iio, A.
Sato, R.
Sakamoto, T.
Kurumatani, H.
author_facet Takenaka, M.
Iio, A.
Sato, R.
Sakamoto, T.
Kurumatani, H.
author_sort Takenaka, M.
collection PubMed
description BACKGROUND: Chronic kidney disease (CKD) is a common progressive and irreversible disease in cats. The efficacy and safety of beraprost sodium (BPS) in cats with CKD have not been evaluated. HYPOTHESIS/OBJECTIVES: To evaluate the efficacy and safety of BPS in the treatment of cats with CKD, as compared to placebo. ANIMALS: Seventy‐four client‐owned cats with naturally occurring CKD. METHODS: Double‐blind, placebo‐controlled, multicenter, prospective, randomized trial. The cats received BPS (55 μg/cat) or a placebo PO q12 h for 180 days. The primary endpoint was prospectively defined as a change in the serum creatinine (sCr), serum phosphorus‐to‐calcium ratio or urine specific gravity (USG). RESULTS: The sCr increased significantly (P = 0.0030) in the placebo group (mean ± SD: 2.8 ± 0.7 to 3.2 ± 1.3 mg/dL) but not in the BPS group (2.4 ± 0.7 to 2.5 ± 0.7 mg/dL). The difference between the groups at day 180 was significant (0.8 mg/dL, 95% CI: 0.2 to 1.3 mg/dL, P = 0.0071). The serum phosphorus‐to‐calcium ratio was significantly (P = 0.0037) increased in the placebo group (0.46 ± 0.10 to 0.52 ± 0.21 mg/dL) but not in the BPS group (0.50 ± 0.08 to 0.51 ± 0.11 mg/dL). There was no significant change in the USG in either group. An adverse event judged as being treatment‐related included vomiting that occurred in 1 case in the placebo group. No clinically relevant change was observed in the CBC and other blood chemistry tests. CONCLUSIONS AND CLINICAL IMPORTANCE: Beraprost sodium treatment was well tolerated and safe in cats with CKD. BPS inhibited the reduction in renal filtration function as measured by sCr increase.
format Online
Article
Text
id pubmed-5787173
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-57871732018-02-08 A Double‐blind, Placebo‐controlled, Multicenter, Prospective, Randomized Study of Beraprost Sodium Treatment for Cats with Chronic Kidney Disease Takenaka, M. Iio, A. Sato, R. Sakamoto, T. Kurumatani, H. J Vet Intern Med SMALL ANIMAL BACKGROUND: Chronic kidney disease (CKD) is a common progressive and irreversible disease in cats. The efficacy and safety of beraprost sodium (BPS) in cats with CKD have not been evaluated. HYPOTHESIS/OBJECTIVES: To evaluate the efficacy and safety of BPS in the treatment of cats with CKD, as compared to placebo. ANIMALS: Seventy‐four client‐owned cats with naturally occurring CKD. METHODS: Double‐blind, placebo‐controlled, multicenter, prospective, randomized trial. The cats received BPS (55 μg/cat) or a placebo PO q12 h for 180 days. The primary endpoint was prospectively defined as a change in the serum creatinine (sCr), serum phosphorus‐to‐calcium ratio or urine specific gravity (USG). RESULTS: The sCr increased significantly (P = 0.0030) in the placebo group (mean ± SD: 2.8 ± 0.7 to 3.2 ± 1.3 mg/dL) but not in the BPS group (2.4 ± 0.7 to 2.5 ± 0.7 mg/dL). The difference between the groups at day 180 was significant (0.8 mg/dL, 95% CI: 0.2 to 1.3 mg/dL, P = 0.0071). The serum phosphorus‐to‐calcium ratio was significantly (P = 0.0037) increased in the placebo group (0.46 ± 0.10 to 0.52 ± 0.21 mg/dL) but not in the BPS group (0.50 ± 0.08 to 0.51 ± 0.11 mg/dL). There was no significant change in the USG in either group. An adverse event judged as being treatment‐related included vomiting that occurred in 1 case in the placebo group. No clinically relevant change was observed in the CBC and other blood chemistry tests. CONCLUSIONS AND CLINICAL IMPORTANCE: Beraprost sodium treatment was well tolerated and safe in cats with CKD. BPS inhibited the reduction in renal filtration function as measured by sCr increase. John Wiley and Sons Inc. 2017-11-13 2018 /pmc/articles/PMC5787173/ /pubmed/29131397 http://dx.doi.org/10.1111/jvim.14839 Text en Copyright © 2017 The Authors. Journal of Veterinary Internal Medicine published by Wiley Periodicals, Inc. on behalf of the American College of Veterinary Internal Medicine. This is an open access article under the terms of the Creative Commons Attribution‐NonCommercial (http://creativecommons.org/licenses/by-nc/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.
spellingShingle SMALL ANIMAL
Takenaka, M.
Iio, A.
Sato, R.
Sakamoto, T.
Kurumatani, H.
A Double‐blind, Placebo‐controlled, Multicenter, Prospective, Randomized Study of Beraprost Sodium Treatment for Cats with Chronic Kidney Disease
title A Double‐blind, Placebo‐controlled, Multicenter, Prospective, Randomized Study of Beraprost Sodium Treatment for Cats with Chronic Kidney Disease
title_full A Double‐blind, Placebo‐controlled, Multicenter, Prospective, Randomized Study of Beraprost Sodium Treatment for Cats with Chronic Kidney Disease
title_fullStr A Double‐blind, Placebo‐controlled, Multicenter, Prospective, Randomized Study of Beraprost Sodium Treatment for Cats with Chronic Kidney Disease
title_full_unstemmed A Double‐blind, Placebo‐controlled, Multicenter, Prospective, Randomized Study of Beraprost Sodium Treatment for Cats with Chronic Kidney Disease
title_short A Double‐blind, Placebo‐controlled, Multicenter, Prospective, Randomized Study of Beraprost Sodium Treatment for Cats with Chronic Kidney Disease
title_sort double‐blind, placebo‐controlled, multicenter, prospective, randomized study of beraprost sodium treatment for cats with chronic kidney disease
topic SMALL ANIMAL
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5787173/
https://www.ncbi.nlm.nih.gov/pubmed/29131397
http://dx.doi.org/10.1111/jvim.14839
work_keys_str_mv AT takenakam adoubleblindplacebocontrolledmulticenterprospectiverandomizedstudyofberaprostsodiumtreatmentforcatswithchronickidneydisease
AT iioa adoubleblindplacebocontrolledmulticenterprospectiverandomizedstudyofberaprostsodiumtreatmentforcatswithchronickidneydisease
AT sator adoubleblindplacebocontrolledmulticenterprospectiverandomizedstudyofberaprostsodiumtreatmentforcatswithchronickidneydisease
AT sakamotot adoubleblindplacebocontrolledmulticenterprospectiverandomizedstudyofberaprostsodiumtreatmentforcatswithchronickidneydisease
AT kurumatanih adoubleblindplacebocontrolledmulticenterprospectiverandomizedstudyofberaprostsodiumtreatmentforcatswithchronickidneydisease
AT adoubleblindplacebocontrolledmulticenterprospectiverandomizedstudyofberaprostsodiumtreatmentforcatswithchronickidneydisease
AT takenakam doubleblindplacebocontrolledmulticenterprospectiverandomizedstudyofberaprostsodiumtreatmentforcatswithchronickidneydisease
AT iioa doubleblindplacebocontrolledmulticenterprospectiverandomizedstudyofberaprostsodiumtreatmentforcatswithchronickidneydisease
AT sator doubleblindplacebocontrolledmulticenterprospectiverandomizedstudyofberaprostsodiumtreatmentforcatswithchronickidneydisease
AT sakamotot doubleblindplacebocontrolledmulticenterprospectiverandomizedstudyofberaprostsodiumtreatmentforcatswithchronickidneydisease
AT kurumatanih doubleblindplacebocontrolledmulticenterprospectiverandomizedstudyofberaprostsodiumtreatmentforcatswithchronickidneydisease
AT doubleblindplacebocontrolledmulticenterprospectiverandomizedstudyofberaprostsodiumtreatmentforcatswithchronickidneydisease